Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trialSarah Brown, Jonathan Wadsley, Laura Moss et al.|BMC Cancer|2019Cited by 39
SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspectiveJonathan Wadsley, Sarah Brown, Rebecca Gregory et al.|British Journal of Radiology|2017Cited by 32
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine TherapyJonathan Wadsley, Sarah Brown, Glenn Flux et al.|Thyroid|2023Cited by 19